All In Biotech

Drug Trial Radar · NCT01135212

The Clinical Study to Evaluate the Efficacy and Safety of Fimasartan in Patients With Mild to Moderate Essential Hypertension

A Randomized, Double-blind, Candesartan-controlled, Parallel Group Comparison Clinical Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan in Patients With Mild to Moderate Essential Hypertension (Phase IIIb)

Last checked: Nov 19, 2026Latest source record: Aug 24, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 290 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

290

Actual

Start

Apr 2010

Primary completion

Apr 2011

Study completion May 2011

Sponsor

Sponsor type
Industry
Collaborators
Kyungpook National University Hospital; Gyeongsang National University Hospital; Keimyung University; Kosin University Gospel Hospital; Daegu Catholic University Medical Center; Dong-A medical center; Pusan National University Yangsan Hospital; Yeungnam University Hospital; Ulsan University Hospital; Inje University; Pusan National University Hospital
First posted
Jun 2, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 19 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this clinical study is to evaluate and compare the efficacy and safety of Fimasartan (60mg / 120mg) with Candesartan(8mg) in patients with mild to moderate hypertension.

Conditions

  • Hypertension

Interventions

  • Fimasartan 60mgDrug

    Fimasartan 60mg for mild to moderate hypertension. Take a tablet(filled in Doubleblind capsule) every morning.

  • Fimasartan 120mgDrug

    Fimasartan 120mg for mild to moderate hypertension. Take a tablet(filled in Doubleblind capsule) every morning.

  • Candesartan cilexetilDrug

    Candesartan 8mg for mild to moderate hypertension. Take a tablet(filled in Doubleblind capsule) every morning.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Sitting Diastolic Blood PressureTime frame: 12weeks from baseline visit

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • KyungPook National University Hospital

    Daegu, Daegu, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.